Cholesterol drug shows promise in leukemia combo trial
NCT ID NCT04512105
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 26 times
Summary
This early-phase study tested adding the cholesterol-lowering drug pitavastatin to the standard targeted therapy venetoclax for people with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find a safe dose and check for side effects. Only 6 people took part, so results are very preliminary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
Conditions
Explore the condition pages connected to this study.